Trial · NCT07080385
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Period 1: Maximum Plasma Concentration (Cmax) of Encaleret and Metabolites M1, and M3 | 5 days | |
| Primary | Period 1: Area Under the Plasma Concentration-time Curve (AUC) of Encaleret and Metabolites M1, and M3 | 5 days | |
| Primary | Period 3: Number of Participants with Albumin-corrected Blood Calcium (cCa) and Urinary Calcium (UCa) Excretion Response | Week 25 | |
| Secondary | Period 1: Change from Baseline in Blood cCa | Baseline up to Day 5 | |
| Secondary | Period 1: Change from Baseline in Blood Intact Parathyroid Hormone (iPTH) Concentration | Baseline up to Day 5 | |
| Secondary | Period 1: Change from Baseline in Blood Phosphate Concentration | Baseline up to Day 5 | |
| Secondary | Period 1: Change from Baseline in Blood 1,25-(OH)2 Vitamin D Concentration | Baseline up to Day 5 | |
| Secondary | Period 1: Change from Baseline in Blood Magnesium Concentration | Baseline up to Day 5 | |
| Secondary | Period 1: Change from Baseline in 24-hour UCa in Toilet Trained Participants | Baseline up to Day 5 | |
| Secondary | Period 1: Change from Baseline in Spot Ratio of UCa/Urinary Creatinine (UCr) In Non-toilet Trained Participants | Baseline up to Day 5 | |
| Secondary | Period 3: Number of Participants with Blood iPTH Within the Reference Range | Week 25 (post-dose) | |
| Secondary | Period 3: Number of Participants with Blood Phosphate Within the Reference Range | Week 25 | |
| Secondary | Period 3: Number of Participants with Blood Magnesium Within the Reference Range | Week 25 | |
| Secondary | Period 3: Number of Participants with Blood 1,25-(OH)2 Vitamin D Within the Reference Range | Week 25 | |
| Secondary | Periods 1, 2, and 3: Change from Baseline in Short Form-10 Health Survey for Children (SF-10) in Participants Aged ≥6 Years | Baseline up to Week 25 | |
| Secondary | Periods 1, 2, and 3: Dose of Calcium Supplements and/or Active Vitamin D Analogs Used as Rescue Therapy | 25 weeks | |
| Secondary | Periods 1, 2, and 3: Dosing Frequency of Calcium Supplements and/or Active Vitamin D Analogs Used as Rescue Therapy | 25 weeks | |
| Secondary | Periods 1, 2, 3, and LTE: Number of Participants with Adverse Events (AEs) and Serious AEs (SAEs) | 145 weeks | |
| Secondary | LTE: Change from Baseline in Blood cCa | Baseline up to 145 weeks | |
| Secondary | LTE: Change from Baseline in Blood iPTH Concentration | Baseline up to 145 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07080385/registered